Skip to main navigation Skip to main content

OPEN ACCESS

- Current Issue
  
  Volume 32 Issue 1
  
  Ahead of Print
  
  Past Issues
  
  Editor-in-Chief : Won Kim
  
  Indexed In
  
  SCIE, MEDLINE, PubMed, PMC, and Scopus
Journal Insights
- 16.9
  
  Impact Factor
- 19.7
  
  Cite Score
- 7 days
  
  First Decision
- 4 days
  
  Publication after Acceptance
View all insights

Editor's Pick

Original Article

Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement
Joseph Rabbat, Boyu Yang, Hye Won Lee, et al. Clin Mol Hepatol 2026;32(1):289-304.

Ahead of Print

COLEC12^high TAMs Orchestrate Lenvatinib Resistance and Cancer Stemness in HCC via Paracrine NRG1-HER2/HER3 Signaling

Jianxing Zhang, Liang Qiao, Zongfeng Wu, et al.
Clinical Implications of Discordant FIB-4 and LSM in MASLD: Integrating Evidence and Optimizing Pathways — A Commentary on the Study by Rabbat et al.

Deliang Huang, Jun Chen
ERBB3 blockade sensitizes HCC to regorafenib after first-line TKI resistance by inhibiting HIF1A-ABCB1 signaling

Baorui Tao, Chenhe Yi, Bo Zhang, et al.

Current Issue

2025 KASL clinical practice guidelines for management of hepatitis C
Eun Sun Jang, Nae Yun Heo, Jae Yoon Jeong, et al. Clin Mol Hepatol 2026;32(1):1-52.
Pediatric metabolic dysfunction–associated steatotic liver disease and the gut microbiome: from research landscape to targeted modulation
Lu Jiang, Lan-Duoduo Du, Jing Zeng, et al. Clin Mol Hepatol 2026;32(1):53-68.
Tumor-based biomarkers and circulating tumor DNA for precision medicine in advanced hepatocellular carcinoma
Sabrina Sidali, Claudia Campani, Jihyun An, et al. Clin Mol Hepatol 2026;32(1):69-90.

Guideline

2025 KASL clinical practice guidelines for management of hepatitis C

Eun Sun Jang, Nae Yun Heo, Jae Yoon Jeong, et al.
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025

Won Sohn, Young-Sun Lee, Soon Sun Kim, et al.
KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease

Mi Na Kim, Ji Won Han, Jihyun An, et al.

Video abstract

Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host–microbe signaling and highlights 2-hydroxyisocaproate as a potential effector
Jiyi Choi, Moon Gyeong Yoon, Se Ha Jang, et al. Clin Mol Hepatol 2026;32(1):239-257.
Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography
Dong Wook Kim, Won Chang, So Yeon Kim, et al. Clin Mol Hepatol 2025;31(4):1285-1297.
Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease
Hye Won Lee, Jae Seung Lee, Mi Na Kim, et al. Clin Mol Hepatol 2025;31(3):1018-1031.

Snapshot

Decoding platelet function in liver cirrhosis: A shift from quantity to quality

Vibhuti Jakhmola, Sukriti Baweja, Chhagan Bihari
Clin Mol Hepatol 2025;31(4):1384-1386.
Interventions targeting the gut-liver axis: A potential treatment strategy for metabolic dysfunction-associated steatotic liver disease

Pingping Jin, Xinyi Lu, Daozhen Chen, et al.
Clin Mol Hepatol 2025;31(3):1100-1102.
Modulation of lymphatic vessels in management of liver disease and complications

Aarti Sharma, Pinky Juneja, Shiv K Sarin, et al.
Clin Mol Hepatol 2025;31(2):665-668.

Most cited articles

Most viewed articles

Most downloaded articles